01/26/2009
TVM Capital promotes Dr. Peter Neubeck to Principal
January 26, 2009, Munich - Dr. Peter Neubeck joined the TVM Capital Life Sciences Practice in early 2008 as a senior associate, based in Munich. As a principal, he will be involved in investment management, deal origination and the evaluation of new investments with an emphasis on clinical development stage to commercial stage investments.
“As a member of the deal team he has shown that he is a great addition to our professional team,” said Dr. Helmut Schühsler, Managing Partner of TVM Capital. “He brings to TVM Capital strong drug development experience and a deep understanding of pharmaceutical markets. His past experience nicely complements our operational expertise and deep scientific, clinical and commercial understanding.”
Prior to joining TVM Capital, he worked at Novartis Pharma as Global Project Leader for the Cardiovascular & Metabolism Business Franchise, and was responsible for the life cycle strategy and development of the novel potential blockbuster antihypertensive Rasilez®/Tekturna®, including the recent FDA approval of the first fixed dose combination Tekturna HCT®. He has completed his medical studies at Ludwig- Maximilians-University München and Harvard Medical School and holds an MBA degree from INSEAD.
Press Contact
Monika Schlesinger
TVM Capital GmbH
Maximilianstr. 35, Eingang C
D- 80539 Munich, Germany
++49 (89) 998 992-0
Nancy Saucier
TVM Capital
101 Arch Street, Suite 1950
Boston, MA 02110, USA
+1 (617) 345 9320
